Plasma- and lipoprotein-associated activity of the platelet activating factor acetylhydrolase (PAF-acetylhydrolase, PAF-AH) plays an important role in inflammation and in atherosclerotic process, which are present in the metabolic syndrome (MS). Paraoxonase 1 (PON1) is an esterase associated with high-density lipoprotein (HDL) which contributes to the anti-atherogenic effects of this lipoprotein. We investigated the activities of both enzymes in 60 patients with MS and 110 age- and sex-matched subjects without it (non-MS group). Plasma PAF-AH activity was higher in the MS compared to the non-MS group, while HDL-PAF-AH and serum PON1 activities were lower in the MS compared to the non-MS group. Univariate regression analysis in the MS group showed that plasma PAF-AH activity was positively associated with systolic blood pressure, whereas HDL-PAF-AH activity was inversely associated with the homeostasis model assessments (HOMA) index. Both associations remained significant in the multivariate regression analysis, suggesting that insulin resistance and systolic hypertension are major determinants for the alterations in plasma and HDL-associated PAF-AH activity among those observed in MS patients.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.plefa.2004.10.021 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Etiology and characteristics of pseudotumoral lesions and tumefactive demyelination in multiple sclerosis.
Mult Scler Relat Disord
December 2024
Faculty of Medicine, University of Belgrade, Serbia; Neurology Clinic, University Clinical Center of Serbia, Serbia. Electronic address:
Article Synopsis
- The study focused on cerebral pseudotumoral lesions (CPTL) greater than 2 cm, primarily in patients referred for evaluation of multiple sclerosis (MS).
- Most of the 75 patients studied had MS (58.7%), with relapsing disease and specific lesion characteristics being significantly more common in this group compared to non-MS patients.
- Key indicators such as headache, the nature of disease progression, and certain MRI traits could help differentiate between MS and non-MS conditions, suggesting a need for further research with larger sample sizes.
The 2024 Report on the Human Proteome from the HUPO Human Proteome Project.
J Proteome Res
December 2024
Institute for Systems Biology, Seattle, Washington 98109, United States.
Article Synopsis
- The Human Proteome Project (HPP) aims to identify every protein-coding gene’s isoform and integrate proteomics into studies of human health and disease.
- Major updates include the retirement of neXtProt as the knowledge base, with UniProtKB now serving as the reference proteome, and GENCODE providing the target protein list.
- Recent data shows that 93% of protein-coding genes have been expressed, leaving 1,273 non-expressed proteins, along with the introduction of a new scoring system for functional annotation of proteins.
Patients with multiple sclerosis have higher rates of worsening following total hip arthroplasty: a propensity-matched analysis.
Hip Int
November 2024
Department of Orthopaedic Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Introduction: The progressive nature of multiple sclerosis (MS) may adversely affect outcomes following total hip arthroplasty (THA). As patient-reported outcome measures (PROMs) in this specific group are not well defined, this study aimed to compare the clinical outcomes and the rates of achieving the minimal clinically important difference for improvement (MCID-I) and worsening (MCID-W) between patients with MS and those without MS undergoing THA.
Methods: We conducted a retrospective analysis of 375 THAs, including 75 MS patients and 300 propensity-matched non-MS patients (4:1), performed between 2016 and 2022.
Impact of discontinuing disease-modifying therapies on health care utilization among midlife patients with multiple sclerosis in the United States.
J Manag Care Spec Pharm
November 2024
Division of Pharmaceutical Outcomes and Policy, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill.
Background: Multiple sclerosis (MS) is a lifelong progressive neurological disease treated primarily with disease-modifying therapies (DMTs). Disease activity tends to decline as patients age. Midlife represents a crossroads where the risks of DMT may outweigh the benefits, prompting providers to consider DMT discontinuation to reduce treatment burden.
View Article and Find Full Text PDFTetraspanins, GLAST and L1CAM Quantification in Single Extracellular Vesicles from Cerebrospinal Fluid and Serum of People with Multiple Sclerosis.
Biomedicines
October 2024
Neuroimmunology Group, Neuroscience Area, Biogipuzkoa Health Research Institute, 20014 San Sebastián, Spain.
This study aimed to unravel the single tetraspanin pattern of extracellular vesicles (EVs), L1CAM and GLAST EV levels as diagnostic biomarkers to stratify people with multiple sclerosis (pwMS), specifically relapsing-remitting (RRMS) and primary progressive (PPMS). The ExoView platform was used to directly track single EVs using a clinically feasible volume of cerebrospinal fluid (CSF) and serum samples. This technology allowed us to examine the patterns of classical tetraspanin and quantify the levels of L1CAM and GLAST proteins, commonly used to immunoisolate putative neuron- and astrocyte-derived EVs.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!